LONDON, June 30, 2026, 22:02 BST
- Rentokil Initial plc (LON:RTO) closed Tuesday at 426.69p, slipping 0.89%. The FTSE 100 was up 0.12%.
- The stock dropped 1.75% over Monday and Tuesday, well above the FTSE 100’s 0.10% loss in those two days.
- North America made up roughly 59% of Rentokil’s Q1 revenue, but organic growth here was 3.9%, trailing Rollins NYSE:ROL, which saw 6.6% organic growth for the group.
London cash trading was closed at the time; the London Stock Exchange reports normal trading runs from 0800 to 1630 local, and London time was 2202 BST.
Rentokil shares dropped again Tuesday, finishing at 426.69p, off 0.89%. The stock opened at 428.10p and touched a session low at 425.40p, according to Investing.com. About 14.49 million shares changed hands, 85% more than the average for June from the same source.
The spread with the index stood out over two days:
| Asset | June 26 close | June 30 close | Move over June 29-30 |
|---|---|---|---|
| Rentokil Initial | 434.30p | 426.69p | -1.75% |
| FTSE 100 | 10,508.02 | 10,497.12 | -0.10% |
The FTSE 100 ended Tuesday up 12.90 points at 10,497.12, a gain of 0.1%. Rentokil shares fell, while the wider blue-chip index managed to stay in positive territory.
Shares are moving because North America is still the main story for Rentokil. The company’s first-quarter update in April showed revenue at $1.677 billion, with $995 million from North America. That’s about 59% of total revenue for the period. CEO Mike Duffy said Rentokil kept “continued momentum in North America” and stuck with a full-year forecast “in line with market expectations.” Rentokil Initial
Peer numbers tell a different story. Rollins, which owns Orkin and trades in the U.S., posted first-quarter revenue at $906 million and organic revenue growth of 6.6%. Rentokil’s North America business grew organically at 3.9%, falling behind by 270 basis points. In April, Rollins CEO Jerry Gahlhoff Jr. pointed to what he called a “resilient business model” and boosted spending on “organic demand generation.” PR Newswire
| Q1 2026 measure | Rentokil Initial | Rollins |
|---|---|---|
| Revenue | $1.677 billion total, $995 million from North America | $906 million |
| Organic revenue growth | 3.4% overall, 3.9% for North America | 6.6% |
| Pest control signal | North America pest control up 4.1% organically | Organic revenue up 6.6% |
Rentokil’s four-day slide has erased the June 24 gain, when the stock finished 2.95% higher at 439.70p. At Tuesday’s close, shares were trading 2.96% below that mark.
Rentokil has picked Rafael “Rafa” Carrasco as its next North America CEO, with a start date of Aug. 3. Carrasco joins from WM, where he handled 200-plus branches and led over 10,000 people across a range of markets. Duffy said Carrasco brings experience managing “field-based, recurring service operations.” Carrasco said he’s looking to drive “operational excellence.” Rentokil Initial
Broker calls haven’t reversed the slide. Panmure Liberum began covering the stock on June 1, setting a buy rating and 563p target, MarketScreener reported. With shares closing at 426.69p on Tuesday, that target means roughly 32% upside.
AJ Bell data shows Rentokil valued around £10.73 billion, with a P/E ratio at 49.56 and dividend yield at 2.14%. Shares are 15.8% down from their 507p high for the year, but still 27.4% over the 334.80p low.
Rentokil is scheduled to report interim results on July 30 and release its Q3 trading update on Oct. 22, according to its investor calendar.
